脊得舒丸联合西药治疗强直性脊柱炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R593.23

基金项目:

国家中医临床研究基地科研专项(2019JDZX083)


Clinical Study on Jideshu Pills Combined with Western Medicine for Ankylosing Spondylitis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察脊得舒丸联合西药治疗强直性脊柱炎的临床疗效及对血清炎症因子、骨代谢水平的影 响。方法:采用随机数字表法将109 例强直性脊柱炎患者分为对照组(54 例) 与观察组(55 例)。对照组给予 常规西药治疗,观察组在对照组基础上联用脊得舒丸治疗。比较2 组治疗前后中医证候积分、脊柱功能指标、 视觉模拟评分法(VAS) 评分及血清骨代谢、炎症因子水平,并评估2 组临床疗效及安全性。结果:治疗后, 观察组总有效率高于对照组(P<0.05)。治疗后,2 组中医证候积分、BASFI、VAS 评分、枕墙距、指地距均 低于治疗前(P<0.05),且观察组治疗后中医证候积分、强直性脊柱炎功能指数(BASFI)、VAS 评分、枕墙 距、指地距均低于对照组(P<0.05)。治疗后,2 组骨形态发生蛋白-2(BMP-2)、骨钙素(BGP)、骨特异性碱 性磷酸酶(BALP) 水平均高于治疗前(P<0.05),且观察组治疗后上述骨代谢指标高于对照组(P<0.05)。 2 组巨噬细胞移动抑制因子(MIF)、肿瘤坏死因子-α (TNF-α)、白细胞介素-23(IL-23) 水平均低于治疗 前(P<0.05),且观察组治疗后MIF、TNF-α、IL-23 水平低于对照组(P<0.05)。2 组不良反应发生率比较, 差异无统计学意义(P>0.05)。结论:脊得舒丸联合西药治疗强直性脊柱炎效果显著,能够有效改善患者骨代 谢和脊柱功能,降低血清炎症因子水平,安全性较高。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Jideshu Pills combined with western medicine for ankylosing spondylitis and its effects on the levels of serum inflammatory factors and bone metabolism. Methods:A total of 109 cases of patients with ankylosing spondylitis were divided into the control group and the observation group according to the random number table method,with 54 and 55 cases in each group respectively. The control group was treated with routine western medicine, and the observation group was additionally treated with Jideshu Pills based on the treatment of the control group. Traditional Chinese medicine (TCM) syndrome scores, spinal function indexes, the Visual Analogue Scale (VAS) scores, and the levels of serum bone metabolism and inflammatory factors were compared before and after treatment between the two groups. Clinical effects and safety were evaluated in the two groups. Results: The total effective rate in the observation group was higher than that in the control group (P< 0.05). After treatment,TCM syndrome scores,Bath Ankylosing Spondylitis Functional Index (BASFI),VAS scores,the occipital bone-to-wall distance,and finger-to-ground distance in the two groups were lower than those before treatment (P<0.05), the TCM syndrome scores, BASFI, VAS scores, the occipital bone-to-wall distance,and finger-to-ground distance in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of bone morphogenetic protein-2 (BMP-2),bone gla protein (BGP),and bone alkaline phosphatase (BALP) in the two groups were higher than those before treatment (P<0.05), and the above bone metabolism indexes in the observation group were higher than those in the control group (P<0.05). The levels of macrophage migration inhibitory factor (MIF), tumor necrosis factor- α (TNF- α), and interleukin- 23 (IL- 23) in the two groups were lower than those before treatment (P<0.05),the levels of MIF,TNF-α,and IL-23 after treatment in the observation group were lower than those in the control group (P<0.05). There was no significant difference being found in the comparison of the incidence of adverse reactions (P>0.05). Conclusion: Jideshu Pills combined with western medicine has significant effects in the treatment of patients with ankylosing spondylitis,which can effectively improve bone metabolism levels and spinal function and reduce the levels of serum inflammatory factors,with high safety.

    参考文献
    相似文献
    引证文献
引用本文

王冰,周子朋.脊得舒丸联合西药治疗强直性脊柱炎临床研究[J].新中医,2023,55(9):120-124

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-05-24
  • 出版日期:
文章二维码